Clinical trials: Heartburn
Gastroesophageal Reflux Disease (GERD)
The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity
It is planned to investigate the effect of dexrabeprazole on gastric acid primarily, and then gastroesophageal reflux disease (GERD) symptoms, intraesophageal acidity (reflux) and impedance kinetics.
- Trial name
- NCT02689999
- Testing
- Dexrabeprazole 10 mg Enteric-Coated Tablets
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 12 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Reflux Oesophagitis
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
The objective of the study was to assess whether the tolerance to the effect of YF476 on gastric pH observed with repeated doses in a previous study in healthy volunteers can be avoided by using smaller doses of YF476.
- Trial name
- NCT01597674
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Heartburn
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment.
- Trial name
- NCT00206024
- Testing
- Esomeprazole magnesium (Nexium)
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Gout, Coronary Artery Disease
Uric Acid Study in Healthy Male Volunteers
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
- Trial name
- NCT00738842
- Testing
- AZD6140
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
This study includes patients with sleep disturbances associated with gastroesophageal reflux disease (GERD) and has 3 treatment arms.
- Trial name
- NCT00628342
- Testing
- Esomeprazole
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Heartburn, Upper Abdominal Pain
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2…
- Conditions
- Heartburn, Upper Abdominal Pain, Nausea, Acid Regurgitation
- Trial name
- NCT00625274
- Testing
- Esomeprazole, Lansoprazole, Pantoprazole
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Gastro-Oesophageal Reflux Disease
PPI Sequencing Study
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NCT00384592
- Testing
- Esomeprazole, Physical exam, Pregnancy test if applicable
- Where
- 14 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Heartburn
A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)
A study in 24 healthy subjects to assess the bioequivalence of Famotidine/Antacid EZ Chew tablet taken without water and with water compared to the Famotidine/Antacid tablet taken with water.
- Trial name
- NCT00944671
- Testing
- famotidine (+) calcium carbonate (+) magnesium hydroxide tablet, Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water, Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Pompe Disease, Glycogen Storage Disease Type II
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
The purpose of this study was to evaluate the efficacy, clinical benefits and safety of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa (Myozyme®) in patients with infantile-onset…
- Trial name
- NCT00701129
- Testing
- Alglucosidase Alfa, Methotrexate, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Genzyme, a Sanofi Company
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca
Heartburn, Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a…
- Trial name
- NCT00637845
- Testing
- Esomeprazole Magnesium, Lansoprazole
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251745
- Testing
- Dexlansoprazole MR
- Where
- 95 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in subjects…
- Trial name
- NCT00321984
- Testing
- Dexlansoprazole MR
- Where
- 153 sites in United States
- Volunteers
- 947 people
- Sponsor
- Takeda
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Heartburn
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton…
- Conditions
- Gastroesophageal Reflux Disease, Heartburn, Regurgitation
- Trial name
- NCT01005251
- Testing
- lesogaberan (AZD3355)
- Where
- United States
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Symptomatic Gastroespohageal Reflux Disease
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will cause damage to the esophagus over time.
- Trial name
- NCT00149851
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 832 people
- Sponsor
- Novartis
Gastroesophageal Reflux Disease, GERD
Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn
- Trial name
- NCT00373334
- Testing
- nizatidine (axid)
- Where
- 26 sites in United States
- Volunteers
- 138 people
- Sponsor
- Braintree Laboratories
Frequent Heartburn
A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
- Trial name
- NCT01286194
- Testing
- Rabeprazole sodium
- Where
- 33 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca